Navigation Links
Arpida Invited to Present Data on Iclaprim at Scientific Conference
Date:4/9/2008

e treatment of patients with hospital-acquired pneumonia (HAP), ventilator-associated pneumonia (VAP) or healthcare associated pneumonia (HCAP).

In January 2008, the US FDA granted authorisation to progress oral iclaprim into a Phase II 'intravenous-to-oral' switch trial. Iclaprim could be offered not only as an intravenous therapy for hospital use in acute situations, but also as an oral formulation, allowing early patient discharge followed by outpatient treatment. This switch could be a valuable instrument in reducing healthcare costs and enhancing patient comfort.

Arpida's fourth most advanced antibiotic programme, AR-709, targets upper and lower respiratory tract infections acquired in the community setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is in Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of thes
'/>"/>

SOURCE Arpida Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Women Invited to Join New Health Registry to Advance Research
2. Pharsight Invited to Present on HIV Modeling and Simulation at ASCPT Annual Meeting
3. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
4. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
5. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Intellect Neurosciences, Inc. to Present Data on Alzheimers Vaccine at 13th International Congress of Immunology Conference
8. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
9. Pre-clinical Data on Recent Advances with HIV VLP Vaccine Presented at AIDS Vaccine 07 Conference
10. Iomai Announces Data from Phase 2 Field Study of Travelers Diarrhea Vaccine Accepted for Presentation at ICAAC
11. Poniard Pharmaceuticals to Present Updated Results of Picoplatin Phase 2 Small Cell Lung Cancer Trial at 12th World Conference on Lung Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... BioPharma, Inc. (PDL) (Nasdaq: PDLI ) today announced ... dividend payment of $1.67 per share to all stockholders ... With this payment, distributions to stockholders for the ... In January 2010, the Company will make a ... 2009 cash distributions and the allocation between dividend income ...
(Date:12/15/2009)... KV Pharmaceutical Company ( KVa/KVb) today announced that ... notice (the "Notice") executed by the Marc S. Hermelin ... requesting that the Board of Directors of the Company ... by written consent relating to the proposed appointment of ... from Ronald J. Kanterman,s departure (the "Director Appointment"). ,, ...
(Date:12/15/2009)... Inc. and Alzheimer,s Weekly today announced the winners of ... designed to help five seniors in their fight to ... five winners will receive a $2,500 Dakim BrainFitness System, ... their brain health and the most widely adopted product ... country. ,, The contest, held to coincide ...
Breaking Medicine Technology:PDL BioPharma Completes December 15 Special Dividend Payment 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 2KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 3KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 4KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 5KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 6KV Pharmaceutical Sets Record Date for Stockholder Action by Written Consent 75 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 25 Seniors Win $2,500 Dakim BrainFitness System to Fight Alzheimer's 3BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 1BCBSGA Announces Decision to Cover H1N1 Vaccine Administration 53494 2Anti growth factor drugs raise hope and concern for treatment of childrens eye diseases 53491 1Anti growth factor drugs raise hope and concern for treatment of childrens eye diseases 53491 2DNA computation gets logical at the Weizmann Institute of Science 9457 1DNA computation gets logical at the Weizmann Institute of Science 9457 2
(Date:12/15/2009)... SUMMARY: The U.S. Senate today rejected ... Care Act that would have helped make prescription ... and legal importation of lower priced drugs from ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ... bring down the skyrocketing costs of prescription drugs. ...
(Date:12/15/2009)... and Health Bureau has invited expressions of interest (EOI) ... hospitals at four sites in the Hong Kong Special ... 31, 2010. ,, At a press conference, the ... the promotion of private hospital development was one of ... Kong government policy announced by Chief Executive Donald Tsang ...
(Date:12/15/2009)... donated to the Lupus Foundation of America and the ... 15 Julian Lennon, son of the legendary ... new digital single, "LUCY," to raise funds for research ... 2010, 100 percent of the proceeds from downloading "LUCY" ... of America (LFA), and the Saint Thomas, Lupus Trust ...
(Date:12/15/2009)... reproductive age were evaluated, Italian study found , , TUESDAY, ... born with cystic fibrosis decreases when screening for potential ... new study finds. , CF neonatal screening has been ... years. Since the 1990s, the area has seen a ... with CF. , Two different CF carrier detection methods ...
(Date:12/15/2009)... needed for protection, CDC says, , , TUESDAY, Dec. 15 ... swine flu vaccine have been recalled by manufacturer Sanofi ... health officials said Tuesday. , According to the U.S. ... testing of the vaccine for children aged 6 months ... lower than required potency levels. "This means that doses ...
Breaking Medicine News(10 mins):Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 2Health News:AARP Disappointed By Senate Vote Against Lower Prescription Drug Prices 3Health News:Hong Kong Government Invites Expressions of Interest in Development of Private Hospitals 2Health News:Julian Lennon and James Scott Cook Release New Charity Single 'LUCY' to Raise Awareness and Funds for Lupus Research 2Health News:Wider Adult Screening May Mean Fewer Children With Cystic Fibrosis 2Health News:Large Recall of Children's Swine Flu Vaccine 2
... smoke have to drink more to feel drunk than ... to their brains, livers and hearts, a new study suggests. ... in rats, which are considered a good model for humans.Since ... drinking more alcohol to get an expected level of intoxication, ...
... shows that probiotics – bacteria like lactobacillus, often added ... infections.The latest study in the field shows children fed ... and require less antibiotic treatments. ,Probiotics are live ... promote healing by changing the balance of healthy and ...
... and upper airway inflammation have been found by researchers.Ulcerative ... inflammatory bowel disease (IBD) - involves inflammation of the ... now revealed a hitherto unexpected complication of IBD.// ... airway inflammation. One involved the larynx - or voice ...
... era where one fights battle towards eternity and hence ... indicators preclude the existance of newer solutions to fight ... on going research , Dr. Simona Giampaoli, from the ... MATISS Project have come out with a view that ...
... do with your genes, and everything to do with your upbringing ... extroverted are believed to be at least partly genetically determined - ... ,The team asked 71 pairs of identical twins and 56 ... five cartoons on a scale of 0 to 10.// A zero ...
... survivors report a good quality of life, despite facing physical ... assume that cancer must lead to a deterioration in your ... Hospital in Carolina carried out a survey on a group ... ,The women were asked a list of questions about the ...
Other Medicine News:
... inserter is designed for insertion of Alcon Acrylic, ... foldable lenses. The blades are taller and thinner, ... This feature prevents lens migration during loading and ... sweet spot on the folded lens optic. The ...
... (HARK) 599 is the first full-featured combination ... patient response on refraction results with visual ... positioned at either 90 or 180 to ... the HARK to the Humphrey Lens Analyzers ...
Neomycin and Polymyxin B Sulfates and Hydrocortisone otic suspension, USP is a sterile antibacterial and anti-inflammatory suspension for otic use....
Prednisolone Acetate ophthalmic suspension USP, 1% is an adrenocortical steroid product prepared as a sterile ophthalmic suspension....
Medicine Products: